Onconova completes enrolment in Phase III study of rigosertib

Clinical-stage biopharmaceutical company Onconova Therapeutics has completed enrolment in its ONTIME pivotal Phase III study of rigosertib in patients with high-risk myelodysplastic syndromes.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news